A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Open-Label Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis (ALAMERE).
A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis.
You may be eligible for the study if you meet the following criteria.
If enrolled, your participation is expected to last approximately 72 weeks (20 Visits) including the Run-In, Treatment, Open-Label.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.